Physician profile
Ahmadreza Moradi
NPI 1851773527
$11,398.23
in general payments reported to CMS, 2019-2025
22 companies · $7,739 in 2025
The $7,739 reported for 2025 was more than what 92% of Cornea and External Diseases Specialist providers received nationally (typical 2025 total: $477).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2020: $282 · 2021: $271 · 2022: $38.33 · 2023: $1,403 · 2024: $1,665 · 2025: $7,739.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,633 · Consulting Fee: $4,125 · Entertainment: $49.49.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,632.91 |
| Consulting Fee | $4,125.00 |
| Entertainment | $49.49 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Tarsus Pharmaceuticals, INC. | $5,404.59 | 2024-2025 | Xdemvy |
| Alcon Vision LLC | $1,634.52 | 2020-2025 | Tryptyr, Clareon Panoptix Pro, Hydrus Microstent |
| Amgen INC. | $650.97 | 2025 | Tepezza |
| Rxsight INC | $643.72 | 2023-2024 | Rxsight Light Delivery Device (Ldd), Rxsight Injector Handpiece, Rxsight Contact Lens |
| Bausch & Lomb Americas INC. | $625.51 | 2023-2025 | Miebo, Xiidra, Envista Mx60 Iol |
| Biotissue Holdings INC. | $535.96 | 2025 | |
| Apellis Pharmaceuticals, INC. | $474.98 | 2023-2025 | Syfovre |
| Lumenis Be INC | $252.05 | 2023 | Optilight |
| Harrow Eye, LLC | $243.24 | 2023-2025 | Iheezo, Vevye |
| Johnson & Johnson Surgical Vision, INC. | $198.23 | 2022-2025 | Tecnis Simplicity, Catalys System, Veritas Vision System |
| Ocular Therapeutix, INC. | $143.42 | 2024 | Dextenza |
| Immunogen, INC. | $136.14 | 2023 | Elahere |
| Sight Sciences, INC. | $111.02 | 2023 | Omni Surgical System |
| Aerie Pharmaceuticals, INC. | $80.33 | 2020 | |
| Glaukos Corporation | $52.72 | 2025 | Idosetr |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Optos, INC. | $49.49 | 2023 | Oct Ophthalmoscope, Panoramic Ophthalmoscope, Nfc-700 |
| Csl Behring | $32.80 | 2024 | Haegarda |
| Sun Pharmaceutical Industries INC. | $31.28 | 2025 | |
| Horizon Therapeutics Plc | $28.60 | 2023 | Tepezza |
| Abbvie INC. | $26.79 | 2024 | |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $24.58 | 2021 | |
| Ani Pharmaceuticals, INC. | $17.29 | 2025 | Purified Cortrophin Gel |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ahmadreza Moradi listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.